Oxycodone and morphine have distinctly different pharmacological profiles: Radioligand binding and behavioural studies in two rat models of neuropathic pain
The DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
Abstract
Previously, we reported that oxycodone is a putative kappa-opioid agonist based on studies where intracerebroventricular (i.c.v.) pre-treatment of rats with the kappa-selective opioid antagonist, nor-binaltorphimine (nor-BNI), abolished i.c.v. oxycodone but not morphine antinociception, whereas pretreatment with i.c.v. naloxonazine (mu-selective antagonist) produced the opposite effects. In the present study, we used behavioural experiments in rat models of mechanical and biochemical nerve injury together with radioligand binding to further examine the pharmacology of oxycodone. Following chronic constriction injury (CCI) of the sciatic nerve in rats, the antinociceptive effects of intrathecal (i.t.) oxycodone, but not i.t. morphine, were abolished by nor-BNI. Marked differences were found in the antinociceptive properties of oxycodone and morphine in streptozotocin (STZ)-diabetic rats. While the antinociceptive efficacy of morphine was abolished at 12 and 24 weeks post-STZ administration, the antinociceptive efficacy of s.c. oxycodone was maintained over 24 weeks, albeit with an approximately 3- to 4-fold decrease in potency. In rat brain membranes irreversibly depleted of mu- and delta-opioid binding sites, oxycodone displaced [(3)H]bremazocine (kappa(2)-selective in depleted membranes) binding with relatively high affinity whereas the selective mu- and delta-opioid ligands, CTOP (D-Phe-Cys-Tyr-D-Trp-Orn-Thr-Pen-Thr-NH(2)) and DPDPE ([D-Pen(2,5)]-enkephalin), respectively, did not. In depleted brain membranes, the kappa(2b)-ligand, leu-enkephalin, prevented oxycodone's displacement of high-affinity [(3)H]bremazocine binding, suggesting the notion that oxycodone is a kappa(2b)-opioid ligand. Collectively, the present findings provide further support for the notion that oxycodone and morphine produce antinociception through distinctly different opioid receptor populations. Oxycodone appears to act as a kappa(2b)-opioid agonist with a relatively low affinity for mu-opioid receptors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PROTEIN MEASUREMENT WITH THE FOLIN PHENOL REAGENT
Lowry, O., Rosebrough, N., Farr, A. L., & Randall, R. (1951) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)52451-6 · Cited by 317,331 · cited 1×
“The protein content of brain membrane preparations was determined according to the method of Lowry et al. (1951) or using a Sigma Micro Protein Determination kit (Procedure # 690); a method based on that of Lowry et al. (1951) and Ohnishi and Barr (1978).”
MethodA peripheral mononeuropathy in rat that produces disorders of pain sensation like those seen in man
Bennett, G. J., & Xie, Y.-K. (1988) · Pain · doi:10.1016/0304-3959(88)90209-6 · Cited by 5,376 · cited 1×
“Chronic constriction injury (CCI) of the sciatic nerve was produced according to the method of Bennett and Xie (1988) in adult male SD rats (222 ± 2.1 g, means ± SEM).”
MethodInfluentialG-protein-coupled receptor heterodimerization modulates receptor function
Jordan, B. A., & Devi, L. A. (1999) · Nature · doi:10.1038/21441 · Cited by 1,166 · cited 1×
“This notion is consistent with that proposed by Jordan and Devi (1999) who showed that the in vitro pharmacological characteristics of d-j-opioid receptor heterodimers are similar to those of the previously pharmacologically defined j2-opioid receptor subtype.”
ResultLack of analgesic effect of opioids on neuropathic and idiopathic forms of pain
Arnér, S., & Meyerson, B. A. (1988) · Pain · doi:10.1016/0304-3959(88)90198-4 · Cited by 991 · cited 1×
“Although the use of opioids for the relief of neuropathic pain is controversial (Arner and Meyerson, 1988), more recent trials have reported significant benefit of oxycodone above placebo (Gimbel et al., 2003; Watson et al., 2003).”
BackgroundMechanisms of hyperalgesian and morphine tolerance: a current view of their possible interactions
Mao, J., Price, D. D., & Mayer, D. J. (1995) · Pain · doi:10.1016/0304-3959(95)00073-2 · Cited by 818 · cited 2×
“Multiple studies have examined the anti-neuropathic properties of morphine in rodent models of neuropathic pain (Backonja et al., 1995; Kayser et al., 1995; Mao et al., 1995; Wegert et al., 1997; Suzuki et al., 1999), but the effect of oxycodone in such models remains poorly investigated.”
BackgroundWatson, P. C. N., Moulin, D., Watt-Watson, J., Gordon, A., & Eisenhoffer, J. (2003) · Pain · doi:10.1016/s0304-3959(03)00160-x · Cited by 510 · cited 2×
“Although the use of opioids for the relief of neuropathic pain is controversial (Arner and Meyerson, 1988), more recent trials have reported significant benefit of oxycodone above placebo (Gimbel et al., 2003; Watson et al., 2003).”
BackgroundControlled-release oxycodone for pain in diabetic neuropathy: A randomized controlled trial
Gimbel, J. S., Richards, P., & Portenoy, R. K. (2003) · Neurology · doi:10.1212/01.wnl.0000057720.36503.2c · Cited by 469 · cited 4×
“These observations are consistent with anecdotal clinical reports that morphine lacks efficacy for the symptomatic relief of painful diabetic neuropathy (PDN) in patients (Attal, 2000).”
BackgroundInfluentialA simplified method of quantitating protein using the biuret and phenol reagents
Ohnishi, S. T., & Barr, J. K. (1978) · Analytical Biochemistry · doi:10.1016/0003-2697(78)90334-2 · Cited by 453 · cited 1×
“The protein content of brain membrane preparations was determined according to the method of Lowry et al. (1951) or using a Sigma Micro Protein Determination kit (Procedure # 690); a method based on that of Lowry et al. (1951) and Ohnishi and Barr (1978).”
MethodLALOVIC, B., KHARASCH, E., HOFFER, C., RISLER, L., LIUCHEN, L., & SHEN, D. (2006) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2006.01.009 · Cited by 413 · cited 6×
“…and membranes prepared from cells expressing cloned l-, d- and j-opioid receptors also reported relatively low affinity binding for oxycodone (Ki = 16.0 ± 2.9 nM) at the l-opioid receptor compared with morphine (Ki = 3.2 ± 0.4 nM) or DAMGO (Ki = 0.21 ± 0.03 nM; Lalovic et al., 2006).”
BackgroundResultInfluentialTakemori, A. E., Ho, B. Y., Naeseth, J. S., & Portoghese, P. S. (1988) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)21011-4 · Cited by 409 · cited 1×
“…oxycodone antinociception in rats are abolished by pretreatment with nor-BNI, an opioid antagonist that does not discriminate between j1 and j2-opioid receptor subtypes (Takemori et al., 1988; Horan et al., 1991), these findings collectively suggest that oxycodone may act as a j2-opioid agonist.”
BackgroundAbram, S. E. (2007) · Yearbook of Anesthesiology and Pain Management · doi:10.1016/s1073-5437(08)70202-x · Cited by 318
Pöyhiä, R., Seppälä, T. T., Olkkola, K. T., & Kalso, E. A. (1992) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1992.tb04090.x · Cited by 304 · cited 2×
“This ensured that circulating concentrations of oxymorphone were very low (Huang et al., 2005), as is the case in humans after systemic oxycodone administration (Pöyhiä et al., 1992; Heiskanen et al., 1998; Lalovic et al., 2006).”
BackgroundThe intrinsic antinociceptive effects of oxycodone appear to be κ -opioid receptor mediated
Ross, F. B., & Smith, M. T. (1997) · Pain · doi:10.1016/s0304-3959(97)00093-6 · Cited by 259 · cited 5×
“…methods in rat models of neuropathic pain and radioligand binding, the present study confirmed and extended our previous in vivo work in rats (Ross and Smith, 1997), showing that the intrinsic antinociceptive effects of oxycodone appear to be mediated by j-opioid receptors, in contrast to…”
BackgroundResultSelf-citationMu receptor binding of some commonly used opioids and their metabolites
Chen, Z. R., Irvine, R. J., Somogyi, A. A., & Bochner, F. (1991) · Life Sciences · doi:10.1016/0024-3205(91)90150-a · Cited by 255 · cited 2×
“…that oxycodone may bind with relatively high affinity to putative j2b-opioid receptors, and with lower affinity to l-opioid receptors, as reported by Chen et al. (1991) for [3H]DAMGO in rat brain homogenate and more recently by Lalovic et al. (2006) for [3H]diprenorphine in membranes from cells…”
MethodInfluentialA pharmacologic analysis of mechanical hyperalgesia in streptozotocin/diabetic rats
Malcangio, M., & Tomlinson, D. R. (1998) · Pain · doi:10.1016/s0304-3959(98)00037-2 · Cited by 236 · cited 1×
“…experiments each performed in duplica * Statistical significance of 2-site vs. 1-site fit for pooled data: F = 12.44, p induced diabetes is in agreement with previous reports (Kamei et al., 1992; Suh et al., 1996; Courteix et al., 1998; Malcangio and Tomlinson, 1998; Nozaki et al., 2005).”
ResultInfluentialEndoh, T., Matsuura, H., Tanaka, C., & Nagase, H. (1992) · PubMed · Cited by 206
Opioid receptor genes inactivated in mice: the highlights
Gavériaux-Ruff, C., & Kieffer, B. L. (2002) · Neuropeptides · doi:10.1054/npep.2002.0900 · Cited by 178 · cited 2×
“In the same study, morphine’s antinociceptive effects were abolished by naloxonazine but not norBNI, a finding consistent with expectations for the prototypic l-opioid agonist, morphine (Pasternak, 2001; Gaveriaux-Ruff and Kieffer, 2002).”
BackgroundResultRothman, R. B., Bykov, V., de Costa, B. R., Jacobson, A. E., Rice, K. C., & Brady, L. S. (1990) · Peptides · doi:10.1016/0196-9781(90)90088-m · Cited by 152 · cited 2×
“…binding assays for each of the major classes of opioid receptors (l, d and j) were performed using rat, or guinea-pig brain membrane preparations in the case of j1-opioid receptor binding, according to previously published methods (Rothman et al., 1985, 1990a,b, 1992) with minor modifications.”
BackgroundMethodInfluentialWegert, S., Ossipov, M. H., Nichols, M. L., Bian, D., Vanderah, T. W., Malan, P. T., & Porreca, F. (1997) · Pain · doi:10.1016/s0304-3959(97)03337-x · Cited by 125 · cited 1×
“Multiple studies have examined the anti-neuropathic properties of morphine in rodent models of neuropathic pain (Backonja et al., 1995; Kayser et al., 1995; Mao et al., 1995; Wegert et al., 1997; Suzuki et al., 1999), but the effect of oxycodone in such models remains poorly investigated.”
BackgroundClemente‐Napimoga, J. T., Parada, C. A., Veiga, M. C. F. D. A., Gear, R. W., & Tambeli, C. H. (2004) · Neuroscience Letters · doi:10.1016/j.neulet.2004.09.048 · Cited by 113 · cited 2×
“…later (Endoh et al., 1992; Wettstein and Grouhel, 1996), norBNI was administered 24 h prior to commencing the experimental procedures, in keeping with other studies where norBNI has been used as a j-selective opioid antagonist (Friese et al., 1997; Schmidt et al., 2002; Clemente et al., 2004).”
MethodBook Review: The Pharmacology of Mu Analgesics: From Patients to Genes
Pasternak, G. W. (2001) · The Neuroscientist · doi:10.1177/107385840100700307 · Cited by 106 · cited 2×
“In the same study, morphine’s antinociceptive effects were abolished by naloxonazine but not norBNI, a finding consistent with expectations for the prototypic l-opioid agonist, morphine (Pasternak, 2001; Gaveriaux-Ruff and Kieffer, 2002).”
BackgroundResultKamei, J., Ohhashi, Y., Aoki, T., Kawashima, N., & Kasuya, Y. (1992) · Brain Research · doi:10.1016/0006-8993(92)90655-s · Cited by 105 · cited 4×
“The long-term results presented herein together with those of short-term studies (Kamei et al., 1992, 1994; Zurek et al., 2001) show that STZ-diabetic rodents are membrane preparations depleted of l- and d-opioid receptors by pre- te.”
BackgroundResultInfluentialSuzuki, R., Chapman, V., & Dickenson, A. H. (1999) · Pain · doi:10.1016/s0304-3959(98)00208-5 · Cited by 99 · cited 1×
“Multiple studies have examined the anti-neuropathic properties of morphine in rodent models of neuropathic pain (Backonja et al., 1995; Kayser et al., 1995; Mao et al., 1995; Wegert et al., 1997; Suzuki et al., 1999), but the effect of oxycodone in such models remains poorly investigated.”
BackgroundAnti-allodynic efficacy of the χ-conopeptide, Xen2174, in rats with neuropathic pain
Nielsen, C. K., Lewis, R. J., Alewood, D., Drinkwater, R. D., Palant, E., Patterson, M., Yaksh, T. L., McCumber, D., & Smith, M. T. (2005) · Pain · doi:10.1016/j.pain.2005.08.002 · Cited by 94
Self-citationChen, S.-R., & Pan, H.-L. (2003) · Anesthesiology · doi:10.1097/00000542-200312000-00026 · Cited by 87 · cited 1×
“Although changes in l-opioid agonist binding affinity or density were not seen in the brain or spinal cord of rats 4 weeks after STZ-induced diabetes (Courteix et al., 1998; Chen and Pan, 2003), impaired G-protein coupling to l-opioid receptors has been documented (Chen et al., 2002).”
BackgroundPöyhiä, R., & Kalso, E. A. (1992) · Pharmacology & Toxicology · doi:10.1111/j.1600-0773.1992.tb00441.x · Cited by 86 · cited 2×
“%) relative to morphine in noninjured rats (Plummer et al., 1990; Pöyhiä and Kalso, 1992), and with the low epidural potency of oxycodone ( 11”
BackgroundAnalysis of [3H] bremazocine binding in single and combinatorial opioid receptor knockout mice
Simonin, F., Slowe, S. J., Becker, J. A. J., Matthes, H. W. D., Filliol, D., Chluba, J., Kitchen, I., & Kieffer, B. L. (2001) · European Journal of Pharmacology · doi:10.1016/s0014-2999(01)00822-6 · Cited by 85 · cited 1×
“Studies in opioid receptor ‘knockout’ mice suggest that j2-opioid receptors may arise from heterodimerization of opioid receptors produced by the 3 known genes encoding opioid receptors l-(MOR), d-(DOR), and j-(KOR), respectively (Simonin et al., 2001).”
BackgroundCourteix, C., Bourget, P., Caussade, F., Bardin, M., Coudoré, F., Fialip, J., & Eschalier, A. (1998) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)37362-8 · Cited by 73 · cited 9×
“All rights reserved. doi:10.1016/j.pain.2007.03.022 Abbreviations: AUC, area under the curve; BIT, 2-(4-ethoxybenzyl)-1-diethylaminoathyl-5-isothiocyanatato-benzimidazoleÆHCl; CCI, chronic constriction injury; CNS, central nervous system; CTOP, D-Phe-Cys-Tyr-D-Trp-Orn-Thr-Pen-Thr-NH2; DA, Dark Agouti; DAMGO, D-Ala 2,…”
BackgroundResultInfluentialFunctional μ Opioid Receptors Are Reduced in the Spinal Cord Dorsal Horn of Diabetic Rats
Chen, S.-R., Sweigart, K. L., Lakoski, J. M., & Pan, H. (2002) · Anesthesiology · doi:10.1097/00000542-200212000-00037 · Cited by 72 · cited 2×
“Although changes in l-opioid agonist binding affinity or density were not seen in the brain or spinal cord of rats 4 weeks after STZ-induced diabetes (Courteix et al., 1998; Chen and Pan, 2003), impaired G-protein coupling to l-opioid receptors has been documented (Chen et al., 2002).”
BackgroundHoran, P. J., de Costa, B. R., Rice, K. C., & Porreca, F. (1991) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)24685-7 · Cited by 67 · cited 2×
“oxycodone antinociception in rats are abolished by pretreatment with nor-BNI, an opioid antagonist that does not discriminate between j1 and j2-opioid receptor subtypes (Takemori et al., 1988; Horan et al., 1991), these findings collectively suggest that oxycodone may act as a j2-opioid agonist.”
BackgroundZurek, J. R., Nadeson, R., & Goodchild, C. S. (2001) · Pain · doi:10.1016/s0304-3959(00)00386-9 · Cited by 62 · cited 2×
“The long-term results presented herein together with those of short-term studies (Kamei et al., 1992, 1994; Zurek et al., 2001) show that STZ-diabetic rodents are membrane preparations depleted of l- and d-opioid receptors by pre- te.”
BackgroundSchmidt, B. L., Tambeli, C. H., Levine, J. D., & Gear, R. W. (2002) · European Journal of Neuroscience · doi:10.1046/j.1460-9568.2002.01915.x · Cited by 59 · cited 2×
“…later (Endoh et al., 1992; Wettstein and Grouhel, 1996), norBNI was administered 24 h prior to commencing the experimental procedures, in keeping with other studies where norBNI has been used as a j-selective opioid antagonist (Friese et al., 1997; Schmidt et al., 2002; Clemente et al., 2004).”
MethodInfluence of polarity on dose-response relationships of intrathecal opioids in rats
Plummer, J. L., Cmielewski, P., Reynolds, G. D., Gourlay, G. K., & Cherry, D. A. (1990) · Pain · doi:10.1016/0304-3959(90)91131-2 · Cited by 58 · cited 4×
“oxycodone ( 2–7%) relative to morphine in noninjured rats (Plummer et al., 1990; Pöyhiä and Kalso, 1992), and with the low epidural potency of oxycodone ( 11%) relative to morphine in patients with post-operative pain (Backlund et al.”
BackgroundInfluentialBačkonja, M.-M., Miletić, G., & Miletić, V. (1995) · Neuroscience Letters · doi:10.1016/0304-3940(95)11844-m · Cited by 56 · cited 2×
“Multiple studies have examined the anti-neuropathic properties of morphine in rodent models of neuropathic pain (Backonja et al., 1995; Kayser et al., 1995; Mao et al., 1995; Wegert et al., 1997; Suzuki et al., 1999), but the effect of oxycodone in such models remains poorly investigated.”
BackgroundRothman, R. B., Bykov, V., Xue, B., Xu, H., de Costa, B. R., Jacobson, A. E., Rice, K. C., Kleinman, J. E., & Brady, L. S. (1992) · Peptides · doi:10.1016/0196-9781(92)90059-c · Cited by 55 · cited 13×
“All rights reserved. doi:10.1016/j.pain.2007.03.022 Abbreviations: AUC, area under the curve; BIT, 2-(4-ethoxybenzyl)-1-diethylaminoathyl-5-isothiocyanatato-benzimidazoleÆHCl; CCI, chronic constriction injury; CNS, central nervous system; CTOP, D-Phe-Cys-Tyr-D-Trp-Orn-Thr-Pen-Thr-NH2; DA, Dark Agouti; DAMGO, D-Ala 2,…”
BackgroundMethodInfluentialLeow, K. P., & Smith, M. T. (1994) · Life Sciences · doi:10.1016/0024-3205(94)00849-3 · Cited by 54 · cited 2×
“However, following i.c.v. administration, oxycodone produces naloxone-sensitive dose-dependent antinociception in the rat with a potency 44% that of i.c.v. morphine (Leow and Smith, 1994; Nielsen et al., 2000).”
BackgroundInfluentialSelf-citationMolecular basis of the Dark Agouti rat drug oxidation polymorphism: importance of CYP2D1 and CYP2D2
Yamamoto, Y., Tasaki, T., Nakamura, A., Iwata, H., Kazusaka, A., Gonzalez, F. J., & Fujita, S. (1998) · Pharmacogenetics · doi:10.1097/00008571-199802000-00010 · Cited by 51 · cited 1×
“DA rats were used for the behavioural experiments in STZ-diabetic rats where oxycodone was administered systemically, because they are genetically deficient in the enzyme (CYP2D1/2D2), which is required to catalyse the O-demethylation of oxycodone to oxymorphone (Yamamoto et al., 1998).”
MethodRothman, R. B., Bykov, V., Danks, J. A., Jacobson, A. E., Burke, T. R., Rice, K. C., & Herkenham, M. A. (1985) · Neuropeptides · doi:10.1016/0143-4179(85)90112-x · Cited by 35 · cited 1×
“…binding assays for each of the major classes of opioid receptors (l, d and j) were performed using rat, or guinea-pig brain membrane preparations in the case of j1-opioid receptor binding, according to previously published methods (Rothman et al., 1985, 1990a,b, 1992) with minor modifications.”
MethodKamei, J., Iwamoto, Y., Misawa, M., Nagase, H., & Kasuya, Y. (1994) · Life Sciences · doi:10.1016/0024-3205(94)90062-0 · Cited by 32 · cited 3×
“The long-term results presented herein together with those of short-term studies (Kamei et al., 1992, 1994; Zurek et al., 2001) show that STZ-diabetic rodents are membrane preparations depleted of l- and d-opioid receptors by pre- te.”
BackgroundInfluentialNi, Q., Xu, H., Partilla, J. S., de Costa, B. R., Rice, K. C., & Rothman, R. B. (1993) · Peptides · doi:10.1016/0196-9781(93)90188-m · Cited by 29 · cited 2×
“Specifically, in ‘depleted’ brain membrane preparations, [3H]bremazocine demonstrated a selective affinity for pharmacologically defined j2-opioid receptors comprising putative j2a- and j2b-opioid subtypes (Ni et al., 1993, 1995).”
BackgroundRothman, R. B., Xu, H., Char, G. U., Kim, A., de Costa, B. R., Rice, K. C., & Zimmerman, D. M. (1993) · Peptides · doi:10.1016/0196-9781(93)90005-2 · Cited by 25 · cited 2×
“Hence, indirect methods employing a saturating concentration of leu-enkephalin (500 nM) were used, as this ligand reportedly has high selectivity for j2b sites (Ki 11 nM), but very low affinity for putative j2a (Ki 5 lM) sites in the CNS (Rothman et al., 1992; Rothman et al., 1993).”
Opioid antagonist profile of SC nor-binaltorphimine in the formalin paw assay
Wettstein, J. G., & Grouhel, A. (1996) · Pharmacology Biochemistry and Behavior · doi:10.1016/0091-3057(95)02043-8 · Cited by 22 · cited 1×
“…effects for up to 4 h following administration and its long-lasting j-selective antagonist effects do not develop until later (Endoh et al., 1992; Wettstein and Grouhel, 1996), norBNI was administered 24 h prior to commencing the experimental procedures, in keeping with other studies where…”
ResultSuh, H., Song, D., Wie, M., Jung, J., Hong, H.-E., Choi, S.-R., & Kim, Y. (1996) · General Pharmacology The Vascular System · doi:10.1016/0306-3623(95)02059-4 · Cited by 21 · cited 1×
“…experiments each performed in duplica * Statistical significance of 2-site vs. 1-site fit for pooled data: F = 12.44, p induced diabetes is in agreement with previous reports (Kamei et al., 1992; Suh et al., 1996; Courteix et al., 1998; Malcangio and Tomlinson, 1998; Nozaki et al., 2005).”
ResultInfluentialNi, Q., Xu, H., Partilla, J. S., de Costa, B. R., Rice, K. C., Kayakiri, H., & Rothman, R. B. (1995) · Peptides · doi:10.1016/0196-9781(95)00091-w · Cited by 18 · cited 2×
“Specifically, in ‘depleted’ brain membrane preparations, [3H]bremazocine demonstrated a selective affinity for pharmacologically defined j2-opioid receptors comprising putative j2a- and j2b-opioid subtypes (Ni et al., 1993, 1995).”
BackgroundInfluentialTiberi, M., & Magnan, J. (1989) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/y89-213 · Cited by 14 · cited 3×
“Due to the reportedly low expression of j1-opioid receptors in rat brain tissue and much higher selective binding ( 10:1) in guinea-pig brain preparations (Tiberi and Magnan, 1989), guinea-pig brain membrane preparations were used for radioligand binding experiments with [3H]U69,593.”
BackgroundMethodResultInfluentialAlbrecht, E. (1997) · Pharmacology Biochemistry and Behavior · doi:10.1016/s0091-3057(96)00480-7 · Cited by 10 · cited 1×
“The observed Ki value (Table 3) was similar to previously reported values (Albrecht et al., 1997).”
Result
Cited by
Basic opioid pharmacology: an update
Pathan, H., & Williams, J. (2012) · British Journal of Pain · doi:10.1177/2049463712438493 · Cited by 671
Uniform assessment and ranking of opioid Mu receptor binding constants for selected opioid drugs
Volpe, D. A., Tobin, G. A. M., Mellon, R. D., Katki, A. G., Parker, R. J., Colatsky, T., Kropp, T. J., & Verbois, S. L. (2011) · Regulatory Toxicology and Pharmacology · doi:10.1016/j.yrtph.2010.12.007 · Cited by 446
“…or cell source for the receptor, and assay methodology (e.g., pre-incubation, ligand and drug concentration) (de Jong et al., 2005; Leslie, 1987; Simantov et al., 1976; Thomasy et al., 2007; Robson et al., 1985; Selley et al., 2003; Nielsen et al., 2007; Titeler et al., 1989; Yoburn et al., 1991).”
BackgroundMethodDeer, T. R., Prager, J., Levy, R., Rathmell, J., Buchser, E., Burton, A., Caraway, D., Cousins, M., De Andrés, J., Diwan, S., et al. (2012) · Neuromodulation: Technology at the Neural Interface · doi:10.1111/j.1525-1403.2012.00476.x · Cited by 327
Kiyatkin, E. A. (2019) · Neuropharmacology · doi:10.1016/j.neuropharm.2019.02.008 · Cited by 192
“Oxycodone, a semi-synthetic opioid analgesic, has slightly lower affinity to μ-receptors compared to morphine but it also interacts with a subtype of k-opioid receptors (Nielsen et al., 2007).”
BackgroundPharmacology of opioids in the treatment of chronic pain syndromes
Vallejo, R. (2011) · Pain Physician · doi:10.36076/ppj.2011/14/e343 · Cited by 124
Metadata
- Authors
- Nielsen, C. K., Ross, F. B., Lotfipour, S., Saini, K. S., Edwards, S. R., & Smith, M. T.
- Venue
- Pain
- Published
- 2007-12
- Volume
- 132
- Issue
- 3
- Pages
- 289-300
- ISSN
- 0304-3959 (ISSN-L)
- OpenAlex
- W2042085544
- Cited by
- 179
- References
- 46
- FWCI
- 7.91
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.